Literature DB >> 26808425

A structured assessment of motor function and behavior in patients with Kleefstra syndrome.

Susanne Schmidt1, Heidi E Nag1, Bente S Hunn1, Gunnar Houge2, Lise B Hoxmark3.   

Abstract

The present study aimed to further our understanding of Kleefstra syndrome, especially regarding motor function and behavioral characteristics. In total, four males and four females between two and 27 years of age with a genetically confirmed diagnosis of Kleefstra syndrome and their parents participated in this study. Four patients had 9q34.3 deletions that caused Euchromatin Histone Methyl Transferase 1 (EHMT1) haplo-insufficiency, and four patients harbored EHMT1 mutations. The motor function was evaluated via systematic observation. Standardized assessments such as the Vineland Adapted Behavior Scales II (VABS II), the Social Communication Questionnaire (SCQ) and the Child or Adult Behavior Checklist (CBCL, ABCL) were used for the behavioral assessment. All patients showed a delayed developmental status. Muscular hypotonia and its manifestations were present in all patients, regardless of their age. The mean values for all VABS II domains (communication, socialization, daily living skills, and motor skills) were significantly lower than the mean of the reference population (p < 0.001), but similar to other rare intellectual disabilities such as Smith-Magenis syndrome and Angelman syndrome. The results from the SCQ indicated that all patient values exceeded the cut-off value, suggesting the possibility of autism spectrum disorder. The behavioral and emotional problems assessed by CBCL and ABCL were less frequent. In conclusion, patients with Kleefstra syndrome present with a broad range of clinical problems in all age groups and are therefore in need of a multidisciplinary follow-up also after their transition into adulthood.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Autism spectrum disorders; Behavior; Growth; Kleefstra syndrome; Motor function; Rare disorder; Sleep

Mesh:

Substances:

Year:  2016        PMID: 26808425     DOI: 10.1016/j.ejmg.2016.01.004

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  4 in total

1.  9q34.3 microduplications lead to neurodevelopmental disorders through EHMT1 overexpression.

Authors:  Maria Teresa Bonati; Chiara Castronovo; Alessandra Sironi; Dario Zimbalatti; Ilaria Bestetti; Milena Crippa; Antonio Novelli; Sara Loddo; Maria Lisa Dentici; Juliet Taylor; Françoise Devillard; Lidia Larizza; Palma Finelli
Journal:  Neurogenetics       Date:  2019-06-17       Impact factor: 2.660

2.  A de novo splice site mutation in EHMT1 resulting in Kleefstra syndrome with pharmacogenomics screening and behavior therapy for regressive behaviors.

Authors:  Amit Kumar Mitra; Jessica Dodge; Jody Van Ness; Israel Sokeye; Brian Van Ness
Journal:  Mol Genet Genomic Med       Date:  2016-12-26       Impact factor: 2.183

3.  A loss-of-function variant in SUV39H2 identified in autism-spectrum disorder causes altered H3K9 trimethylation and dysregulation of protocadherin β-cluster genes in the developing brain.

Authors:  Shabeesh Balan; Yoshimi Iwayama; Tetsuo Ohnishi; Mikiko Fukuda; Atsuko Shirai; Ayumi Yamada; Sara Weirich; Maren Kirstin Schuhmacher; Kalarickal Vijayan Dileep; Toshihiro Endo; Yasuko Hisano; Kaoru Kotoshiba; Tomoko Toyota; Takeshi Otowa; Hitoshi Kuwabara; Mamoru Tochigi; Akiko Watanabe; Hisako Ohba; Motoko Maekawa; Manabu Toyoshima; Tsukasa Sasaki; Kazuhiko Nakamura; Masatsugu Tsujii; Hideo Matsuzaki; Kam Y J Zhang; Albert Jeltsch; Yoichi Shinkai; Takeo Yoshikawa
Journal:  Mol Psychiatry       Date:  2021-07-15       Impact factor: 15.992

4.  EHMT1 mosaicism in apparently unaffected parents is associated with autism spectrum disorder and neurocognitive dysfunction.

Authors:  Anneke de Boer; Karlijn Vermeulen; Jos I M Egger; Joost G E Janzing; Nicole de Leeuw; Hermine E Veenstra-Knol; Nicolette S den Hollander; Hans van Bokhoven; Wouter Staal; Tjitske Kleefstra
Journal:  Mol Autism       Date:  2018-01-25       Impact factor: 7.509

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.